Surface Phenotype of the Cell Lines
| Surface Molecule . | Leukemic Blasts . | SAS413 . | SAS527 . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Uninfected . | HHV-6A+ . | HHV-6B+ . | Uninfected . | HHV-6A+ . | HHV-6B+ . | |||||
| Day 12 . | Day 12 . | Day 210 . | Day 12 . | Day 210 . | Day 12 . | Day 210 . | ||||
| CD2 | 0 | 0.9 | 1.3 | 0.1 | 0 | 1.6 | 0.8 | 0.1 | 0.8 | 0.1 |
| CD3 | 0 | 0 | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD4 | 0 | 0 | 0.4 | 0.2 | 0 | 0.2 | 0 | 0 | 0 | 0 |
| CD5 | 0 | 0.4 | 0.7 | 0.2 | 0 | 1.0 | 0.7 | 0 | 0.6 | 0 |
| CD7 | 0 | 0.2 | 0.3 | 0.3 | 0.1 | 1.4 | 0.8 | 0.2 | 0.5 | 0.2 |
| CD8 | 0 | 0.5 | 0.9 | 0.1 | 0 | 1.1 | 0.4 | 0 | 0.7 | 0 |
| CD9 | 0.4 | 20.0 | 27.8 | 13.4 | 36.5 | 97.6 | 96.3 | 96.0 | 92.6 | 93.7 |
| CD10 | 9.1 | 2.0 | 0.1 | 0.3 | 0.1 | 5.4 | 7.3 | 0.7 | 4.5 | 1.2 |
| CD11b | 0 | 0 | 0 | 0.2 | 0 | 5.2 | 5.7 | 0 | 9.9 | 0 |
| CD13 | 86.8 | 80.0 | 70.7 | 86.9 | 77.1 | 94.7 | 91.9 | 99.5 | 91.2 | 99.8 |
| CD14 | 46.5 | 30.9 | 41.5 | 43.5 | 37.6 | 22.3 | 33.5 | 21.0 | 31.5 | 24.9 |
| CD16 | 0.2 | 0.3 | 0.3 | 3.2 | 0.1 | 0.1 | 1.4 | 0 | 1.3 | 0 |
| CD19 | 0 | 0.1 | 0.3 | 0.2 | 0 | 0.4 | 0.4 | 0 | 0.5 | 0 |
| CD20 | 0.2 | 0.2 | 0.3 | 2.9 | 0 | 1.8 | 1.8 | 0.4 | 2.2 | 0.4 |
| CD21 | 19.9 | 0.5 | 15.9 | 29.4 | 0.1 | 0.9 | 0.1 | 0 | 0.2 | 0.1 |
| CD25 | 0 | 0.4 | 0.2 | 0.1 | 0 | 7.6 | 2.3 | 0 | 2.6 | 0 |
| CD33 | 99.8 | 99.5 | 99.4 | 99.5 | 99.8 | 92.7 | 99.0 | 97.5 | 99.2 | 98.9 |
| CD34 | 0 | 0 | 0 | 0.2 | 0 | 93.4 | 97.8 | 61.8 | 97.8 | 63.1 |
| CD41a | 15.4 | 34.4 | 30.6 | 30.5 | 58.5 | 5.6 | 1.6 | 5.5 | 3.1 | 8.3 |
| CD56 | 0.4 | 0.1 | 0.5 | 0.2 | 0 | 94.9 | 99.8 | 98.5 | 99.9 | 99.3 |
| HLA-DR | 0.2 | 0.4 | 1.0 | 1.0 | 0.1 | 4.5 | 5.2 | 0 | 5.8 | 0 |
| Glycophorin A | ND | 76.3 | 95.0 | 99.0 | 73.5 | 4.1 | 8.1 | 1.8 | 8.3 | 3.3 |
| Surface Molecule . | Leukemic Blasts . | SAS413 . | SAS527 . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Uninfected . | HHV-6A+ . | HHV-6B+ . | Uninfected . | HHV-6A+ . | HHV-6B+ . | |||||
| Day 12 . | Day 12 . | Day 210 . | Day 12 . | Day 210 . | Day 12 . | Day 210 . | ||||
| CD2 | 0 | 0.9 | 1.3 | 0.1 | 0 | 1.6 | 0.8 | 0.1 | 0.8 | 0.1 |
| CD3 | 0 | 0 | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD4 | 0 | 0 | 0.4 | 0.2 | 0 | 0.2 | 0 | 0 | 0 | 0 |
| CD5 | 0 | 0.4 | 0.7 | 0.2 | 0 | 1.0 | 0.7 | 0 | 0.6 | 0 |
| CD7 | 0 | 0.2 | 0.3 | 0.3 | 0.1 | 1.4 | 0.8 | 0.2 | 0.5 | 0.2 |
| CD8 | 0 | 0.5 | 0.9 | 0.1 | 0 | 1.1 | 0.4 | 0 | 0.7 | 0 |
| CD9 | 0.4 | 20.0 | 27.8 | 13.4 | 36.5 | 97.6 | 96.3 | 96.0 | 92.6 | 93.7 |
| CD10 | 9.1 | 2.0 | 0.1 | 0.3 | 0.1 | 5.4 | 7.3 | 0.7 | 4.5 | 1.2 |
| CD11b | 0 | 0 | 0 | 0.2 | 0 | 5.2 | 5.7 | 0 | 9.9 | 0 |
| CD13 | 86.8 | 80.0 | 70.7 | 86.9 | 77.1 | 94.7 | 91.9 | 99.5 | 91.2 | 99.8 |
| CD14 | 46.5 | 30.9 | 41.5 | 43.5 | 37.6 | 22.3 | 33.5 | 21.0 | 31.5 | 24.9 |
| CD16 | 0.2 | 0.3 | 0.3 | 3.2 | 0.1 | 0.1 | 1.4 | 0 | 1.3 | 0 |
| CD19 | 0 | 0.1 | 0.3 | 0.2 | 0 | 0.4 | 0.4 | 0 | 0.5 | 0 |
| CD20 | 0.2 | 0.2 | 0.3 | 2.9 | 0 | 1.8 | 1.8 | 0.4 | 2.2 | 0.4 |
| CD21 | 19.9 | 0.5 | 15.9 | 29.4 | 0.1 | 0.9 | 0.1 | 0 | 0.2 | 0.1 |
| CD25 | 0 | 0.4 | 0.2 | 0.1 | 0 | 7.6 | 2.3 | 0 | 2.6 | 0 |
| CD33 | 99.8 | 99.5 | 99.4 | 99.5 | 99.8 | 92.7 | 99.0 | 97.5 | 99.2 | 98.9 |
| CD34 | 0 | 0 | 0 | 0.2 | 0 | 93.4 | 97.8 | 61.8 | 97.8 | 63.1 |
| CD41a | 15.4 | 34.4 | 30.6 | 30.5 | 58.5 | 5.6 | 1.6 | 5.5 | 3.1 | 8.3 |
| CD56 | 0.4 | 0.1 | 0.5 | 0.2 | 0 | 94.9 | 99.8 | 98.5 | 99.9 | 99.3 |
| HLA-DR | 0.2 | 0.4 | 1.0 | 1.0 | 0.1 | 4.5 | 5.2 | 0 | 5.8 | 0 |
| Glycophorin A | ND | 76.3 | 95.0 | 99.0 | 73.5 | 4.1 | 8.1 | 1.8 | 8.3 | 3.3 |
The expression of surface molecules on SAS413 and SAS527 was examined by flow cytometric analysis at day 12 or day 210 after inoculation with HHV-6A or HHV-6B. Results are expressed as the percentage of positive cells.
Abbreviation: ND, not determined.